scispace - formally typeset
A

A. Makedos

Researcher at Aristotle University of Thessaloniki

Publications -  23
Citations -  545

A. Makedos is an academic researcher from Aristotle University of Thessaloniki. The author has contributed to research in topics: Polycystic ovary & Obstetrics and gynaecology. The author has an hindex of 10, co-authored 22 publications receiving 471 citations.

Papers
More filters
Journal ArticleDOI

Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome

TL;DR: Women with PCOS have increased serum concentrations of CVD risk markers compared with controls, yet with significant between-study heterogeneity, to provide high-quality evidence on the relation between PCOS and CVD.
Journal ArticleDOI

Homocysteine, folic acid and B12 serum levels in pregnancy complicated with preeclampsia

TL;DR: It is concluded that in this study homocysteine levels are significantly elevated in patients with preeclampsia compared with control group, while no vitamin deficiencies were observed.
Journal ArticleDOI

Transdermal testosterone pretreatment in poor responders undergoing ICSI: a randomized clinical trial.

TL;DR: Testosterone pretreatment failed to increase the number of cumulus-oocyte complexes (COCs) retrieved by more than 1.5 as compared with no pretreatment in poor responders undergoing ICSI, suggesting that pretreatment with 10 mg of transdermal testosterone for 21 days could be a viable option to improve poor ovarian response to testosterone.
Journal Article

Operative vaginal delivery in singleton term pregnancies: short-term maternal and neonatal outcomes.

TL;DR: Results of the present study indicate that both modes of instrumental vaginal delivery are safe with respect to maternal morbidity and neonatal trauma, however, forceps application increases the risk of neonatal compromise consequently necessitating their admission in the NICU.
Journal ArticleDOI

Corifollitropin alfa compared with follitropin beta in poor responders undergoing ICSI: a randomized controlled trial

TL;DR: The use of corifollitropin alfa in poor responders is promising since it could simplify ovarian stimulation without compromising its outcome and a multivariable analysis adjusting for all the potential baseline differences confirmed this finding.